search
Back to results

House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma (MITRA)

Primary Purpose

Asthma

Status
Completed
Phase
Phase 3
Locations
Germany
Study Type
Interventional
Intervention
ALK HDM AIT Placebo
ALK HDM AIT 6 DU
ALK HDM AIT 12 DU
Sponsored by
ALK-Abelló A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Asthma focused on measuring HDM, AIT, asthma, asthma exacerbation, House dust mite induced asthma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • A clinical relevant history consistent with house dust mite induced asthma of at least 1 year prior to trial entry.
  • Use of an appropriate amount of inhaled corticosteroid for the control of asthma symptoms.
  • Documented reversible airway obstruction.
  • Suitable level of asthma control.
  • FEV1 ≥ 70% of predicted value.
  • Positive Skin Prick Test response to Der pte and/or Der far.
  • Positive specific IgE against Der pte and/or Der far (≥ IgE Class 2; ≥ 0.70 KU/L).

Key Exclusion Criteria:

  • A clinical history of persistent allergic asthma or rhinitis caused by an allergen to which the subject is regularly exposed and sensitised (except house dust mites).
  • A clinical history of intermittent allergic asthma or rhinitis if the seasonal allergen is causing symptoms in the period from October to March.
  • Any clinically relevant chronic disease.

Sites / Locations

  • Universitätsklinikum Rostock, Abteilung für Pneumologie Zentrum für Innere Medizin, Ernst Heydemann Strasse 6

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Placebo Comparator

Experimental

Experimental

Arm Label

Placebo

ALK HDM AIT 6 DU

ALK HDM AIT 12 DU

Arm Description

Outcomes

Primary Outcome Measures

Time to first moderate or severe asthma exacerbation after ICS reduction

Secondary Outcome Measures

Difference in changes in immunological parameters (IgE, IgG4)
Time to first severe asthma exacerbation after ICS reduction
Frequency of asthma exacerbations following ICS reduction
The average overall symptom score.
Symptom free days
Number and percentage of subjects with treatment emergent AEs

Full Information

First Posted
August 26, 2011
Last Updated
January 27, 2017
Sponsor
ALK-Abelló A/S
Collaborators
Ergomed, ACM Pivotal Global Central Laboratory
search

1. Study Identification

Unique Protocol Identification Number
NCT01433523
Brief Title
House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma
Acronym
MITRA
Official Title
Efficacy of ALK House Dust Mite Allergy Immunotherapy Tablet in Subjects With House Dust Mite Induced Asthma. The MITRA Trial
Study Type
Interventional

2. Study Status

Record Verification Date
January 2017
Overall Recruitment Status
Completed
Study Start Date
August 2011 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
February 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ALK-Abelló A/S
Collaborators
Ergomed, ACM Pivotal Global Central Laboratory

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The purpose of this trial is to investigate if treatment with house dust mite allergen immunotherapy tablet can reduce the risk of asthma exacerbation in subjects with house dust mite induced asthma.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Asthma
Keywords
HDM, AIT, asthma, asthma exacerbation, House dust mite induced asthma

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
834 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Title
ALK HDM AIT 6 DU
Arm Type
Experimental
Arm Title
ALK HDM AIT 12 DU
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
ALK HDM AIT Placebo
Intervention Description
Oral lyophilisate, Placebo, to be administered sublingually once daily
Intervention Type
Drug
Intervention Name(s)
ALK HDM AIT 6 DU
Intervention Description
Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.
Intervention Type
Drug
Intervention Name(s)
ALK HDM AIT 12 DU
Intervention Description
Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.
Primary Outcome Measure Information:
Title
Time to first moderate or severe asthma exacerbation after ICS reduction
Time Frame
Measured during the last 6 months of the trial
Secondary Outcome Measure Information:
Title
Difference in changes in immunological parameters (IgE, IgG4)
Time Frame
Measured at the end of the trial
Title
Time to first severe asthma exacerbation after ICS reduction
Time Frame
Measured during the last 6 months of the trial
Title
Frequency of asthma exacerbations following ICS reduction
Time Frame
Measured during the last 6 months of the trial
Title
The average overall symptom score.
Time Frame
Measured during the last 6 months of the trial
Title
Symptom free days
Time Frame
Measured during the last 6 months of the trial
Title
Number and percentage of subjects with treatment emergent AEs
Time Frame
At end of trial

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: A clinical relevant history consistent with house dust mite induced asthma of at least 1 year prior to trial entry. Use of an appropriate amount of inhaled corticosteroid for the control of asthma symptoms. Documented reversible airway obstruction. Suitable level of asthma control. FEV1 ≥ 70% of predicted value. Positive Skin Prick Test response to Der pte and/or Der far. Positive specific IgE against Der pte and/or Der far (≥ IgE Class 2; ≥ 0.70 KU/L). Key Exclusion Criteria: A clinical history of persistent allergic asthma or rhinitis caused by an allergen to which the subject is regularly exposed and sensitised (except house dust mites). A clinical history of intermittent allergic asthma or rhinitis if the seasonal allergen is causing symptoms in the period from October to March. Any clinically relevant chronic disease.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christian Virchow, Prof.Dr.med.
Organizational Affiliation
Dept. fof Pneumology, University Clinic Rostock, Ernst-Heydemann-Str. 6, 18057 Rostock, Germany
Official's Role
Principal Investigator
Facility Information:
Facility Name
Universitätsklinikum Rostock, Abteilung für Pneumologie Zentrum für Innere Medizin, Ernst Heydemann Strasse 6
City
Rostock
ZIP/Postal Code
18057
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
32926419
Citation
Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020 Sep 14;9(9):CD011293. doi: 10.1002/14651858.CD011293.pub3.
Results Reference
derived

Learn more about this trial

House Dust Mite Treatment of Asthma. The MITRA Trial House Dust Mite Treatment of Asthma

We'll reach out to this number within 24 hrs